The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...

In an important regulatory win for Denmark’s Novo Nordisk (NOV: N), the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, ...

TDA's Canine Decontamination Kit is exclusively available from Mantel Technologies. This kit provides a safe and effective means of decontaminating dogs exposed to toxic substances. TDA Research ...

Exelixis plans on completing the currently ongoing $500... 20 fév 2025 Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis ...

Seladelpar leads to improvements in biochemical markers and pruritus in patients with primary biliary cholangitis (PBC), according to interim results from an open-label, long-term, phase 3 clinical ...